scholarly journals Randomized, double-blind trial of chitosan for body weight reduction

1999 ◽  
Vol 53 (5) ◽  
pp. 379-381 ◽  
Author(s):  
MH Pittler ◽  
NC Abbot ◽  
EF Harkness ◽  
E Ernst
Keyword(s):  
Body Weight ◽  
Weight Reduction ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Body Weight Reduction

Gastric Emptying, Body Weight and Symptoms in Primary Anorexia Nervosa

1993 ◽  
Vol 162 (3) ◽  
pp. 398-402 ◽  
Author(s):  
Georg Stacher ◽  
Thalia-Anthi Abatzi-Wenzel ◽  
Stefan Wiesnagrotzki ◽  
Helmar Bergmann ◽  
Christa Schneider ◽  
...  
Keyword(s):  
Body Weight ◽  
Anorexia Nervosa ◽  
Gastric Emptying ◽  
Motor Activity ◽  
Eating Behaviour ◽  
Gastric Retention ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Gastric Motor Activity

In a double-blind trial, 12 out-patients with primary anorexia nervosa received, for six weeks, either 10 mg cisapride or placebo, three times a day. Cisapride accelerated gastric emptying of a radiolabelled semisolid meal in all six patients; five gained weight and symptoms of gastric retention ameliorated in four. With placebo, three of six had emptying enhanced, four gained weight, and one's symptoms improved. For another six weeks, all patients received cisapride. In five of the patients who had received cisapride, emptying further accelerated or remained stable; in one it slowed. Of the six patients who received placebo, four had emptying accelerated, five gained weight, and symptoms improved in four. Longer administration of cisapride may, by enhancing gastric motor activity, alleviate symptoms of retention and thus help to change eating behaviour.

scholarly journals A prospective, randomized, double-blind trial to compare body weight-adjusted and fixed doses of palonosetron for preventing postoperative nausea and vomiting in obese female patients

PLoS ONE ◽  
2020 ◽  
Vol 15 (1) ◽  
pp. e0227490
Author(s):  
Nathalia Gouveia de Araujo Ferreira ◽  
Ismar Lima Cavalcanti ◽  
Alexandra Rezende Assad ◽  
Louis Barrucand ◽  
Estêvão Luiz Carvalho Braga ◽  
...  
Keyword(s):  
Body Weight ◽  
Postoperative Nausea ◽  
Postoperative Nausea And Vomiting ◽  
Nausea And Vomiting ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Female Patients ◽  
Obese Female

scholarly journals Impact of Masked Replacement of Sugar-Sweetened with Sugar-Free Beverages on Body Weight Increases with Initial BMI: Secondary Analysis of Data from an 18 Month Double–Blind Trial in Children

PLoS ONE ◽  
2016 ◽  
Vol 11 (7) ◽  
pp. e0159771 ◽  
Author(s):  
Martijn B. Katan ◽  
Janne C. de Ruyter ◽  
Lothar D. J. Kuijper ◽  
Carson C. Chow ◽  
Kevin D. Hall ◽  
...  
Keyword(s):  
Body Weight ◽  
Secondary Analysis ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial

scholarly journals IQP-VV-102, a Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Barbara Grube ◽  
Udo Bongartz ◽  
Felix Alt
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Weight Reduction ◽  
Short Term ◽  
Double Blind ◽  
Efficacy Analysis ◽  
Body Weight Reduction ◽  
Obese Subjects ◽  
The Individual ◽  
Primary Efficacy Analysis

The individual ingredients in IQP-VV-102 have demonstrated promising effects in reducing sugar and starch digestion, which potentially leads to weight loss. The trial objective was to evaluate the safety and efficacy of IQP-VV-102 in reducing body weight in overweight and obese subjects. 120 overweight and obese individuals aged 18 to 60 years were randomly assigned to 2 treatment arms (IQP-VV-102 and placebo). The trial was conducted in 2 study centres in Berlin, Germany. The primary efficacy analysis was conducted on 117 subjects (IQP-VV-102:N=54; placebo:N=59), comparing the weight loss effect at baseline and 12 weeks after randomization. There was a statistically significant reduction in mean body weight of 3.29 kg (SD 2.30) in the IQP-VV-102 group compared to 0.83 kg (SD 2.00) in the placebo groupp<0.001. There were no serious or product-related adverse events that were reported over the combined period of 14 weeks. The findings suggested that IQP-VV-102 is effective and safe in body weight reduction in overweight and obese individuals in the short term. The study is registered under clinicaltrials.gov asNCT01681069.

Sign in / Sign up

Export Citation Format

Share Document